Exploring Genetic Testing for Ehlers-Danlos Syndrome, Classic Type

Medically reviewed by Brandon Colby, MD, last reviewed Oct 28, 2026

Short answer: Genetic testing can confirm classic Ehlers-Danlos syndrome by finding changes in genes that make type V collagen, mainly COL5A1 and COL5A2. It is most useful when symptoms are unclear or overlap with other connective tissue disorders. A doctor or genetic counselor can explain what a result means for you and your family.

Update coming in December 2026: The criteria used to diagnose Ehlers-Danlos syndrome (EDS) and hypermobility spectrum disorders (HSD) are being updated for the first time since 2017. If you already have a diagnosis, you do not need to be reevaluated just because the classification is changing. Read our EDS diagnostic criteria update to see what changes for you.

Understanding Ehlers-Danlos Syndrome, Classic Type

Ehlers-Danlos Syndrome (EDS), classic type, is a rare genetic connective tissue disorder that primarily affects the skin, joints, and blood vessels. Individuals with this condition often experience hypermobility, skin hyperextensibility, and fragile tissue. Although EDS is a rare condition, its impact on those affected can be profound, leading to a range of complications if not diagnosed and managed early.

The Role of Genetic Testing in Diagnosing Ehlers-Danlos Syndrome

Genetic testing has emerged as a pivotal tool in diagnosing Ehlers-Danlos Syndrome, classic type. This advanced technique allows for the identification of specific genetic mutations associated with the disorder, providing a more definitive diagnosis than clinical assessment alone. The utilization of genetic testing can significantly aid in the early detection and management of EDS, offering patients a clearer understanding of their condition.

Pinpointing Genetic Mutations

Genetic testing can identify mutations in the COL5A1, COL5A2, and other genes responsible for the production of type V collagen, which is crucial for connective tissue integrity. By pinpointing these mutations, healthcare providers can confirm the presence of EDS, classic type, with greater accuracy. This is particularly beneficial when clinical symptoms are ambiguous or overlap with other connective tissue disorders.

Facilitating Early Intervention

One of the most significant advantages of genetic testing is its ability to facilitate early intervention. By diagnosing EDS at an early stage, healthcare providers can implement preventive measures to manage symptoms and mitigate complications. This proactive approach can improve the quality of life for individuals with EDS and reduce the risk of severe health issues such as joint dislocations, skin tears, and vascular complications.

Guiding Family Planning Decisions

Genetic testing not only benefits the individual diagnosed with EDS but also provides valuable information for family planning. Since EDS is a hereditary disorder, understanding the genetic mutations involved can help prospective parents assess the risk of passing the condition on to their children. This information can guide family planning decisions and encourage genetic counseling for at-risk families.

Challenges and Considerations in Genetic Testing for EDS

Despite its benefits, genetic testing for Ehlers-Danlos Syndrome, classic type, is not without challenges. The rarity of the condition means that not all healthcare providers are familiar with the nuances of genetic testing for EDS. Additionally, the cost and accessibility of genetic testing can be prohibitive for some patients. It is essential for healthcare systems to address these barriers to ensure that all individuals with suspected EDS have access to accurate diagnostic tools.

Conclusion

In conclusion, genetic testing represents a powerful tool in the diagnosis and management of Ehlers-Danlos Syndrome, classic type. By identifying specific genetic mutations, facilitating early intervention, and guiding family planning decisions, genetic testing offers significant benefits to individuals with EDS and their families. As awareness of this rare condition grows, it is crucial for healthcare systems to ensure that genetic testing is accessible and utilized effectively to improve patient outcomes.

What Is the December 2026 EDS Diagnostic Criteria Update?

The Ehlers-Danlos Society is expected to publish an updated classification framework for the Ehlers-Danlos syndromes and hypermobility spectrum disorders in December 2026, the first major update since 2017. If you already have a diagnosis, you do not need to be reevaluated solely because the classification is changing. See how Sequencing is preparing in our guide to the EDS classification update.

Research on Hypermobile EDS and Dysautonomia

Sequencing and the Norris Lab at the Medical University of South Carolina have opened a research study on hypermobile EDS (hEDS) and dysautonomia. If you already have whole genome sequencing with Sequencing, you can choose whether to take part. Participation is voluntary, data is de-identified, and individual results are not returned. Read why we are launching our patient driven genetic study for hypermobile Ehlers-Danlos syndrome and dysautonomia.

Get Tested With Whole Genome Sequencing

Whole genome sequencing reads 100% of your DNA, which includes the COL5A1 and COL5A2 genes. Sequencing's Kit Bundles include a Whole Genome Sequencing kit and Next Gen Disease Screening, which analyzes your genome for more than 15,000 conditions. Bring your results to a doctor who knows connective tissue disorders.

Shop All Whole Genome Sequencing Kit Bundles

Frequently Asked Questions About Classic Ehlers-Danlos Syndrome

What is classic Ehlers-Danlos syndrome?

Classic Ehlers-Danlos syndrome is a rare genetic connective tissue disorder that mainly affects the skin, joints and blood vessels. People with it often have hypermobile joints, skin that stretches more than usual and fragile tissue.

Which genes are linked to classic Ehlers-Danlos syndrome?

Changes in the COL5A1 and COL5A2 genes, which help make type V collagen, are linked to classic EDS. Type V collagen is important for the strength of connective tissue.

Can genetic testing confirm classic Ehlers-Danlos syndrome?

Yes. Under the 2017 international criteria, finding a COL5A1 or COL5A2 variant is the standard test to confirm classic Ehlers-Danlos syndrome, and one is found in more than 90% of people with a clinical diagnosis. Testing is especially helpful when symptoms are unclear or overlap with other connective tissue disorders.

How does early diagnosis help?

An early diagnosis lets care teams put preventive measures in place to manage symptoms and lower the risk of complications such as joint dislocations, skin tears and poor wound healing.

Is classic Ehlers-Danlos syndrome inherited?

Yes. It is a hereditary disorder, so a person who has it can pass it on to their children. A genetic counselor can help at risk families understand the chances and talk through family planning.

Does Sequencing test for classic Ehlers-Danlos syndrome?

Sequencing's whole genome sequencing reads 100% of your DNA, which includes the COL5A1 and COL5A2 genes. Bring your results to a doctor or genetic counselor who can explain what they mean for you.

References

Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017. doi:10.1002/ajmg.c.31552
Morais P, Ferreira O, Magina S. Classic Ehlers-Danlos syndrome: case report and brief review of literature. Acta Dermatovenerol Croat. 2013;21:118-122. PubMed 24001420

This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. Talk to a qualified healthcare provider about your own health.